statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Alto Neuroscience rises 10.8%

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today reported financial results for the full year ended December 31, 2023, and highlighted recent corporate progress. 2024 is shaping up to be a...

Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights

Alto Neuroscience: Potential First-In-Class Approach To Targeting CNS Disorders...

Alto Neuroscience: Potential First-In-Class Approach To Targeting CNS Disorders

Alto Neurosciences (NYSE:ANRO  Get Free Report) quiet period is set to end on Wednesday, March 13th. Alto Neuroscience had issued 8,040,000 shares in its IPO on February 2nd. The total...

Alto Neuroscience, Inc.'s Quiet Period Will End  on March 13th (NYSE:ANRO)

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the companys board of directors. Dr. Radhakrishnan is an accomplished industry executive...

Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today announced that company management will participate in the following upcoming investor conferences: Jefferies Biotech on the Bay Summit, March...

Alto Neuroscience to Participate in Upcoming Investor Conferences

Robert W. Baird assumed coverage on shares of Alto Neuroscience (NYSE:ANRO  Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The brokerage issued an outperform rating...

Alto Neuroscience (NYSE:ANRO) Now Covered by Analysts at Robert W. Baird

Research analysts at Jefferies Financial Group started coverage on shares of Alto Neuroscience (NYSE:ANRO  Get Free Report) in a research report issued on Tuesday, MarketBeat Ratings reports...

Alto Neuroscience (NYSE:ANRO) Now Covered by Jefferies Financial Group

Investment analysts at Stifel Nicolaus began coverage on shares of Alto Neuroscience (NYSE:ANRO  Get Free Report) in a report released on Tuesday, Marketbeat reports. The brokerage set a...

Alto Neuroscience (NYSE:ANRO) Now Covered by Stifel Nicolaus

Robert W. Baird started coverage on shares of Alto Neuroscience (NYSE:ANRO  Free Report) in a report published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an...

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.

Watchers	85
52-Wk Low	$12.78
52-Wk High	$24.00

Volume	51,592.00
52-Wk High	$24.00
52-Wk Low	$12.78

ANRO Alto Neuroscience Inc.

About

Feed

News

Sentiment

Fundamentals